OBJECTIVE: To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level. METHODS AND RESULTS: A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA(2) levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; P=0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoprotein-associated phospholipaseA(2) may potentially relate to impaired HDL remodeling. CONCLUSIONS: Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level.
OBJECTIVE: To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level. METHODS AND RESULTS: A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA(2) levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; P=0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoprotein-associated phospholipaseA(2) may potentially relate to impaired HDL remodeling. CONCLUSIONS: Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level.
Authors: B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab Journal: J Clin Invest Date: 1995-12 Impact factor: 14.808
Authors: Alexander Thompson; Emanuele Di Angelantonio; Nadeem Sarwar; Sebhat Erqou; Danish Saleheen; Robin P F Dullaart; Bernard Keavney; Zheng Ye; John Danesh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: Bernadette A C van Acker; Gert-Jan Botma; Aeilko H Zwinderman; Jan Albert Kuivenhoven; Geesje M Dallinga-Thie; Eric J G Sijbrands; Jolanda M A Boer; Jacob C Seidell; J Wouter Jukema; John J P Kastelein; Hans Jansen; Adrie J M Verhoeven Journal: Atherosclerosis Date: 2007-12-27 Impact factor: 5.162
Authors: Reecha Sofat; Aroon D Hingorani; Liam Smeeth; Steve E Humphries; Philippa J Talmud; Jackie Cooper; Tina Shah; Manjinder S Sandhu; Sally L Ricketts; S Matthijs Boekholdt; Nicholas Wareham; Kay Tee Khaw; Meena Kumari; Mika Kivimaki; Michael Marmot; Folkert W Asselbergs; Pim van der Harst; Robin P F Dullaart; Gerjan Navis; Dirk J van Veldhuisen; Wiek H Van Gilst; John F Thompson; Pamela McCaskie; Lyle J Palmer; Marcello Arca; Fabiana Quagliarini; Carlo Gaudio; François Cambien; Viviane Nicaud; Odette Poirer; Vilmundur Gudnason; Aaron Isaacs; Jacqueline C M Witteman; Cornelia M van Duijn; Michael Pencina; Ramachandran S Vasan; Ralph B D'Agostino; Jose Ordovas; Tricia Y Li; Sakari Kakko; Heikki Kauma; Markku J Savolainen; Y Antero Kesäniemi; Anton Sandhofer; Bernhard Paulweber; Jose V Sorli; Akimoto Goto; Shinji Yokoyama; Kenji Okumura; Benjamin D Horne; Chris Packard; Dilys Freeman; Ian Ford; Naveed Sattar; Valerie McCormack; Debbie A Lawlor; Shah Ebrahim; George Davey Smith; John J P Kastelein; John Deanfield; Juan P Casas Journal: Circulation Date: 2009-12-21 Impact factor: 29.690
Authors: Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah Journal: Clin Chem Date: 2016-11-03 Impact factor: 8.327
Authors: Genevieve A Woodard; Maria M Brooks; Emma Barinas-Mitchell; Rachel H Mackey; Karen A Matthews; Kim Sutton-Tyrrell Journal: Menopause Date: 2011-04 Impact factor: 2.953
Authors: Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol Journal: Lancet Date: 2011-09-09 Impact factor: 79.321
Authors: James P Corsetti; Peter Salzman; Dan Ryan; Arthur J Moss; Wojciech Zareba; Charles E Sparks Journal: PLoS One Date: 2013-07-09 Impact factor: 3.240